bioRxivCancer BiologyPreprint
Interaction between DNA damage response, translation and apoptosome determines cancer susceptibility to TOP2 poisons
C. U. Awah, L. Chen, M. Bansal, A. Mahajan, J. Winter, M. Lad, L. Warnke, E. Gonzalez-Buendia, C. Park, D. Zhang, E. Feldstein, D. Yu, M. Zannikou, I. Balyasnikova, R. Martuscello, S. Konermann, B. Gyorffy, K. Burdett, D. Scholtens, R. Stupp, A. Ahmed, P. Hsu, A. M. Sonabend
Abstract
Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer. We show that glioblastoma (GBM), the most malignant of all primary brain tumors in adults is responsive to TOP2 poisons. To identify genes that confer susceptibility to this drug in gliomas, we performed a genome-scale CRISPR knockout screen with etoposide. Genes involved in protein synthesis and DNA damage were implicated in etoposide susceptibility. To define potential biomarkers for TOP2 poisons, CRISPR hits were overlapped with genes whose expression correlates with susceptibility to this drug across glioma cell lines, revealing ribosomal protein subunit RPS11, 16, 18 as putative biomarkers for response to TOP2 poisons. Loss of RPS11 impaired the induction of pro-apoptotic gene APAF1 following etoposide treatment, and led to resistance to this drug and doxorubicin. The expression of these ribosomal subunits was also associated with susceptibility to TOP2 poisons across cell lines from multiple cancers.\n\nGraphical Abstract\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=93 SRC=\"FIGDIR/small/614024v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (14K):\norg.highwire.dtl.DTLVardef@310f7org.highwire.dtl.DTLVardef@14ed578org.highwire.dtl.DTLVardef@a0d9c0org.highwire.dtl.DTLVardef@37f59a_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: whole-genome sequencing
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide
C. U. Awah, J. Winter, O. Ogunwobi·bioRxiv·Aug 11, 2021
- Tyrosyl-DNA phosphodiesterase 1 and topoisomerase I activities as predictive indicators for Glioblastoma susceptibility to genotoxic agents
W. Wang, M. Rodriguez-Silva, … Y.-C. Tse-Dinh·bioRxiv·Jul 14, 2019
- Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
M. N. Stillger, C.-Y. Chen, … O. Schilling·bioRxiv·Oct 19, 2022
- Acquisition and reversal of glioblastoma chemoresistance are mediated by the Rho GTPase pathway
Yuli Thamires Magalhães, Viktor Kalbermatter Boell, Fábio Luís Forti·Molecular Cancer TherapeuticsPeer-reviewed·Oct 28, 2025
- PARP inhibitor counteracts Temozolomide Resistance in Glioblastoma Multiforme
Édouard Samarut, Gaston Tabourel, … Aurélien A. Sérandour·bioRxiv·Dec 13, 2024
- Mitochondrial sites of contact with the nucleus aid in chemotherapy evasion of glioblastoma cells
Daniela Strobbe, Mardja Bueno, … Michelangelo Campanella·bioRxiv·Aug 27, 2024